lung-cancer

Documents about lung-cancer

• Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)#230495ClinicalTrials.gov
• Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform#287533ClinicalTrials.gov
• Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer#340174IRIS
• Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC#125832ClinicalTrials.gov
• Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study#261501ClinicalTrials.gov
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV#426781ClinicalTrials.gov
• Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors#394761ClinicalTrials.gov
• Marker-based CRISPR screens identify POU2F1 as a regulator of DLL3 and neuroendocrine identity in small cell lung cancer#165966bioRxiv / medRxiv
• NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts#180366ClinicalTrials.gov
• Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors#303750ClinicalTrials.gov
• A Retrospective Real-World Study Based on RATIONALE-307#426772ClinicalTrials.gov
• IgA vasculitis associated with chronic myelomonocytic leukemia#442515HAL (France)
• Predicting lung cancer survival with attention-based CT slices combination.#9738PubMed
• Immunopeptidomics-guided identification of functional neoantigens in non-small cell lung cancer#10111bioRxiv / medRxiv
• Explainability Through Human-Centric Design for XAI in Lung Cancer Detection#147088arXiv (OAI)
• National Survey of Lung Cancer Screening Eligibility in United States Veterans.#148300NCBI PubMed Central
• ctDNA as a Biomarker for Treatment in Advanced NSCLC#148734ClinicalTrials.gov
• Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer#160355ClinicalTrials.gov
• An inhalable microbe-oncolytic virus consortium for lung cancer treatment.#223006NCBI PubMed Central
• Interventions for smoking cessation in people undergoing lung cancer screening.#244400NCBI PubMed Central
• Daratumumab in STK11 Mutated NSCLC#245496ClinicalTrials.gov
• Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer#311904HAL (France)
• Germline determinants of risk and molecular subtype in young-onset lung cancer#438524bioRxiv / medRxiv
• Detection of lung cancer using Kronecker mobile forward harmonic net.#439240NCBI PubMed Central
• A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.#201789ClinicalTrials.gov
• CHEMICAL DESIGN OF NIR-I AND NIR-II DYES FOR FLUORESCENCE-GUIDED SURGERY OF NON-SMALL CELL LUNG CANCER#263713ScholarlyCommons at Penn
• Neoadjuvant chemo-immunotherapy in a kidney transplant recipient with locally advanced non-small cell lung cancer: a case report of a therapeutic dilemma#308243HAL (France)
• Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer#442092ClinicalTrials.gov
• Multi-omics analysis identified SPRR2D as a potential biomarker for tumor prognosis and immune microenvironment infiltration: a pan-cancer perspective#5080Europe PMC
• Effect of preoperative respiratory prehabilitation on cardiopulmonary function in patients undergoing lung resection for non-small cell lung cancer: a randomized controlled trial.#258431NCBI PubMed Central
• Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors#181763ClinicalTrials.gov
• Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)#125851ClinicalTrials.gov
• Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study#178175HAL (France)
• Postoperative circulating cell-free DNA (cfDNA) dynamics as an early indicator of molecular residual disease in lung cancer: preliminary results and correlation with TNM status, adjuvant therapy, and clinical outcome#245139ARPHA OAI-PMH Endpoint
• A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy#279518ClinicalTrials.gov
• Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC#332765ClinicalTrials.gov
• Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy#272351ClinicalTrials.gov
• Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC#387147ClinicalTrials.gov
• A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors#123471ClinicalTrials.gov
• Uniportal Robotic-Assisted Versus Video-Assisted Thoracoscopic Surgery for Anatomical Lung Resection in Non-Small Cell Lung Cancer: A Comparative Single-Center Cohort Study.#275286NCBI PubMed Central
• Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients#146458ClinicalTrials.gov
• The present and future of lung cancer screening: latest evidence.#165842NCBI PubMed Central
• Inherited genetic risk factors in young-onset lung cancer#180182bioRxiv / medRxiv
• Implementation of the NHS England Lung Cancer Screening Programme over 5 years.#219038NCBI PubMed Central
• Application of artificial intelligence in lung cancer diagnosis, therapy, and prognosis.#219087NCBI PubMed Central
• Advances in translational lung cancer research in 2025: a narrative review.#281030NCBI PubMed Central
• Applying artificial intelligence to ensure high quality and equitable lung cancer screening.#281056NCBI PubMed Central
• Cellular Immunotherapy Synergize Chemotherapy in Patients With Stage IV NSCLC#432876ClinicalTrials.gov
• Precision greenness exposure is associated with lung cancer risk in medicare beneficiaries.#442961NCBI PubMed Central
• Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial#161257HAL (France)